MG-1102 is a first-in-class dual binder of monomeric tau and pre-miRNA-146a, exhibiting specific inhibition of miRNA146a with IC 50 values of 0.21 mM for double-labeled pre-miRNA146a and 0.36 mM for mono-labeled pre-miRNA146a. It interacts with tau monomers with a K d of 3.21 mM as determined by surface plasmon resonance (SPR), positioning it as a potential multi-target-directed ligand (MTDL) for Alzheimer’s disease (AD) [1].
MMG-11 inhibits both TLR2/1 and TLR2/6 signaling (IC50s: 1.7 μM for Pam3CSK4-induced hTLR2/1 and 5.7 μM for Pam2CSK4-induced hTLR2/6 responses). MMG-11 is an effective and selective human TLR2 antagonist with low cytotoxicity.